Patent application EP16201293A (EP), filed 2016-11-30
Publication number: EP3173476A1
Title: IMMUNITY INDUCER
Abstract: [0001]    Disclosed is an immunity inducer. The immunity inducer comprises virus like particles; the virus like particles comprise a virus-derived outer coat protein and an antigen-bound protein comprising an exogenous antigen; the outer coat protein constitutes an outer coat of the virus like particles, and the antigen-bound protein is comprised in the outer coat; and the virus like particles induce an immune effect of a living body on the antigen.
IPC codes: A61K  39/    00            A I
C12N   7/    00            A I
Claims: number: 1
text: An immunity inducer, wherein
the immunity inducer comprises virus like particles;
the virus like particles comprise a virus-derived outer coat protein and an antigen-bound protein comprising an exogenous antigen;
the outer coat protein constitutes an outer coat of the virus like particles, and the antigen-bound protein is comprised in the outer coat.
number: 2
text: The immunity inducer according to claim 1, wherein the outer coat protein is derived from a virus in the genus Polyomavirus.
number: 3
text: The immunity inducer according to claim 2, wherein the virus in the genus Polyomavirus is SV40, and the outer coat protein is VP1.
number: 4
text: The immunity inducer according to any of claims 1 to 3, wherein the antigen-bound protein is a fusion protein of the antigen and an inner peptide.
number: 5
text: The immunity inducer according to claim 4, wherein the inner peptide is derived from a virus in the genus Polyomavirus, and the inner protein is VP2 and/or VP3.
number: 6
text: The immunity inducer according to claim 4 or 5, wherein an amino acid sequence of the inner peptide comprises an amino acid sequence represented by SEQ ID No. 9 or SEQ ID NO. 11.
number: 7
text: The immunity inducer according to any of claims 1 to 6, wherein the immunity inducer is a solid preparation, a semisolid preparation, a liquid preparation, an injection, or a suppository.
number: 8
text: The immunity inducer according to any of claims 1 to 7 for use in inducing immunity effect of the living body on the antigen by administering the immunity inducer.
number: 9
text: A method for producing the immunity inducer according to any of claims 1 to 8, comprising a step of contacting a virus-derived outer coat protein with an antigen-bound protein to prepare virus like particles.
number: 10
text: The method according to claim 9, comprising
a step of introducing a DNA encoding the outer coat protein and a DNA encoding the antigen-bound protein into a host cell to express the outer coat protein and the antigen-bound protein in the host cell, thereby obtaining the outer coat protein and the antigen-bound protein.
number: 11
text: The method according to claim 9 or 10, wherein the host cell is selected from a group consisting of an insect cell, Escherichia coli, a yeast and a plant cell.
number: 12
text: The method according to any of claims 9 to 11, wherein the outer coat protein is VP1 of SV40, and the antigen-bound protein comprises VP2 and/or VP3 of SV40.
number: 13
text: The method according to any of claims 9 to 12, wherein the immunity inducer is a solid preparation, a semisolid preparation, a liquid preparation, an injection, or a suppository.
Office action: search_report, dated 2017-05-31
Rejection reasons: novelty_epc_54
Prior art cited: ref_id: US2014286978A1
ref_type: patent
severity: background
ref_id: - MAEDA ET AL.: "Invertebrate Cell system and Applications", vol. 1, 1989, CRC PRESS, pages: 167 - 181
ref_type: npl
severity: background
ref_id: - INOUE ET AL: "Engineering of SV40-based nano-capsules for delivery of heterologous proteins as fusions with the minor capsid proteins VP2/3", JOURNAL OF BIOTECHNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 134, no. 1-2, 3 January 2008 (2008-01-03), pages 181 - 192, XP022500142, ISSN: 0168-1656, DOI: 10.1016/J.JBIOTEC.2007.12.006
ref_type: npl
severity: background
ref_id: - TEGERSTEDT KARIN ET AL: "A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 65, no. 13, 1 July 2005 (2005-07-01), pages 5953 - 5957, XP002387780, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-05-0335
ref_type: npl
severity: background
ref_id: - MASAAKI KAWANO ET AL: "SV40 virus-like particles as an effective delivery system and its application to a vaccine carrier", EXPERT REVIEW OF VACCINES, vol. 12, no. 2, 9 February 2013 (2013-02-09), GB, pages 199 - 210, XP055348348, ISSN: 1476-0584, DOI: 10.1586/erv.12.149
ref_type: npl
severity: background
ref_id: - ABBING A ET AL: "Efficient intracellular delivery of a protein and a low molecular weight substance via recombinant polyomavirus-like particles", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 279, no. 26, 25 June 2004 (2004-06-25), pages 27410 - 27421, XP002354397, ISSN: 0021-9258, DOI: 10.1074/JBC.M313612200
ref_type: npl
severity: background
ref_id: - TEUNISSEN ERIK A ET AL: "Production and biomedical applications of virus-like particles derived from polyomaviruses", JOURNAL OF CONTROLLED RELEASE, vol. 172, no. 1, 31 August 2013 (2013-08-31), pages 305 - 321, XP028772934, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2013.08.026
ref_type: npl
severity: background
ref_id: - TEGERSTEDT K ET AL: "MURINE POLYOMAVIRUS VIRUS-LIKE PARTICLES (VLPS) AS VECTORS FOR GENE AND IMMUNE THERAPY AND VACCINES AGAINST VIRAL INFECTIONS AND CANCER", ANTICANCER RESEARCH - INTERNATIONAL JOURNAL OF CANCER RESEARCH AND TREATMENT, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 25, no. 4, 1 July 2005 (2005-07-01), pages 2601 - 2608, XP009068573, ISSN: 0250-7005
ref_type: npl
severity: background
ref_id: - INOUE ET AL, "Engineering of SV40-based nano-capsules for delivery of heterologous proteins as fusions with the minor capsid proteins VP2/3", JOURNAL OF BIOTECHNOLOGY, ELSEVIER, AMSTERDAM, NL, (20080103), vol. 134, no. 1-2, doi:10.1016/J.JBIOTEC.2007.12.006, ISSN 0168-1656, pages 181 - 192, XP022500142 [X] 1-5,7,9-13 * abstract * * Paragraphs 2.2., 2.3 and 2.6 * [I] 6,8
ref_type: npl
severity: novelty_destroying
ref_id: - TEGERSTEDT KARIN ET AL, "A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20050701), vol. 65, no. 13, doi:10.1158/0008-5472.CAN-05-0335, ISSN 0008-5472, pages 5953 - 5957, XP002387780 [X] 1,2,4,5,7-11,13 * abstract * * See "Materials and methods" and  "Vaccination and Tumor Challenge" * [I] 3,6,12
ref_type: npl
severity: novelty_destroying
ref_id: - MASAAKI KAWANO ET AL, "SV40 virus-like particles as an effective delivery system and its application to a vaccine carrier", EXPERT REVIEW OF VACCINES, GB, (20130209), vol. 12, no. 2, doi:10.1586/erv.12.149, ISSN 1476-0584, pages 199 - 210, XP055348348 [A] 1-13 * Page 203: "Delivery of foreign proteins into cells by SV40-VLPs";; figure 1 *
ref_type: npl
severity: background
ref_id: - ABBING A ET AL, "Efficient intracellular delivery of a protein and a low molecular weight substance via recombinant polyomavirus-like particles", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, (20040625), vol. 279, no. 26, doi:10.1074/JBC.M313612200, ISSN 0021-9258, pages 27410 - 27421, XP002354397 [A] 1-13
ref_type: npl
severity: background
ref_id: - TEUNISSEN ERIK A ET AL, "Production and biomedical applications of virus-like particles derived from polyomaviruses", JOURNAL OF CONTROLLED RELEASE, (20130831), vol. 172, no. 1, doi:10.1016/J.JCONREL.2013.08.026, ISSN 0168-3659, pages 305 - 321, XP028772934 [A] 1-13
ref_type: npl
severity: background
ref_id: - TEGERSTEDT K ET AL, "MURINE POLYOMAVIRUS VIRUS-LIKE PARTICLES (VLPS) AS VECTORS FOR GENE AND IMMUNE THERAPY AND VACCINES AGAINST VIRAL INFECTIONS AND CANCER", ANTICANCER RESEARCH - INTERNATIONAL JOURNAL OF CANCER RESEARCH AND TREATMENT, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, (20050701), vol. 25, no. 4, ISSN 0250-7005, pages 2601 - 2608, XP009068573 [A] 1-13
ref_type: npl
severity: background
Final disposition: pending (2017-05-31)